PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT03650452: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies
Official title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies
Conditions: Epilepsy
Dravet Syndrome
Lennox-Gastaut Syndrome
Summary: The purpose of this study is to investigate the effect on the frequency of all seizures (convulsive and drop) in participants treated with TAK-935 compared to placebo.
Interventions:
description: TAK-935 tablets or mini-tablets.
name: TAK-935
type: Drug
description: TAK-935 placebo-matching tablets or mini-tablets.
name: Placebo
type: Drug
Study arms:
design_group_description: TAK-935 placebo-matching tablets, orally or via gastrostomy tube (G-tube)/percutaneous endoscopic gastrostomy (PEG), twice a day (BID) up to Week 20.
design_group_title: Placebo
design_group_type: Placebo Comparator
design_group_description: TAK-935 tablets orally or via G-tube/PEG tube, BID. Participants weighing <60 kg received total daily dose of study drug calculated based on body weight. Participants weighing ≥60 kg at Baseline, were administered with 200 mg/day followed by 400 mg/day, then 600 mg/day, up to Week 20.
design_group_title: TAK-935
design_group_type: Experimental
Sponsor: Takeda Pharmaceutical Co., Ltd.
Collaborators: Ovid Therapeutics, Inc.
Drug name mappings:
name: Soticlestat
lang: EN
Clinical trial NCT02772237: The Impact of Riboflavin on Sports-related Concussion
Official title: The Impact of Riboflavin on Sports-related Concussion: A Randomized Control Trial
Conditions: Sports-related Concussion
Summary: The purpose of this study is to investigate the effectiveness of riboflavin to decrease the duration of time for a student-athlete to return to participation in sports after a sports related concussion.
Interventions:
description: Riboflavin 400mg daily
name: Riboflavin
other_name: Vitamin B2
type: Biological
name: Placebo
type: Biological
Study arms:
design_group_description: Riboflavin 400mg daily
design_group_title: Treatment group
design_group_type: Active Comparator
design_group_description: Placebo
design_group_title: Placebo group
design_group_type: Placebo Comparator
Sponsor: University of Virginia
Collaborators: James Madison University
Drug name mappings:
name: 维生素B2
lang: CN
name: Vitamin B2
lang: EN
Clinical trial NCT04223661: Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
Official title: Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy in Elderly, Frail Newly Diagnosed Myeloma (MMY2035)
Conditions: Multiple Myeloma
Summary: The purpose of this study is to determine if using a subject's baseline frailty score to guide the dosing of lenalidomide in a combination with dexamethasone and daratumumab (DRd lite).
Interventions:
description: Lenalidomide will be administered PO on Days 1 through 21 of each 28 day cycle at the dose according to the frailty score and creatinine clearance.
name: Lenalidomide Pill
type: Drug
description: Dexamethasone will be administered at 20 mg per week. During weeks when the subject receives an infusion of daratumumab, dexamethasone will be administered on infusion days at a dose of 20 mg IV before the infusion.
name: Dexamethasone
type: Drug
description: Daratumumab (1800 mg) will be administered by SC injection by manual push over approximately 3 - 5 minutes in the abdominal subcutaneous tissues in the left/right locations, alternating between individual doses. The volume of the SC solution will be 15 mL for the 1800 mg dose
name: Daratumumab
type: Drug
Study arms:
design_group_description: Starting dose of lenalidomide in subjects who are intermediately fit (frailty score of 1) will be 10 mg day 1-21 of 28 day cycle and escalate to 15 mg<br/>All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial.
design_group_title: Frailty score 1
design_group_type: Experimental
design_group_description: Starting dose of lenalidomide in frail subjects (frailty score of 2 or higher) will be 5 mg day 1-21 of 28 day cycle, and escalate to 10 mg.<br/>All subjects will receive 20mg Dexamathasone weekly (split dosing is allowed) and 16mg Daratumumab (cycle 1-2 on days 1,8,15 and 22. Cycles 3-6 on days 1 and 15. Cycle 7 and beyond on day 1) during the course of the trial.
design_group_title: Frailty Score 2 or above
design_group_type: Experimental
Sponsor: Indiana University
Collaborators: Janssen Scientific Affairs LLC
Drug name mappings:
name: 来那度胺
lang: CN
name: Lenalidomide
lang: EN
name: レナリドミド水和物
lang: JP
name: 达雷妥尤单抗
lang: CN
name: Daratumumab
lang: EN
name: ダラツムマブ（遺伝子組換え）
lang: JP
name: 地塞米松
lang: CN
name: Dexamethasone
lang: EN
name: デキサメタゾン
lang: JP
Clinical trial NCT05231798: Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition
Official title: Cholinergic Integrity in Down Syndrome in Association With Aging, Alzheimer's Disease Pathology, and Cognition
Conditions: Down Syndrome
Down Syndrome, Partial Trisomy 21
Alzheimer Disease
Summary: Progressive age-related cognitive deficits occurring in both AD and DS have been connected to the degeneration of several neuronal populations, but mechanisms are not fully elucidated. The most consistent neuronal losses throughout the progression of AD are seen in cholinergic neurons where these losses negatively affect cognition, particularly in attention, learning, and memory formation. Evidence of reduced cholinergic integrity in DS is largely limited to animal models and post-mortem human data. The investigators propose to use molecular, functional, and structural biomarkers to assess the cholinergic integrity in adults with DS. The investigators anticipate using the data gathered in this pilot study to inform future study designs to determine AD risk stratification in DS by identifying individuals who show an accelerated decline in cholinergic integrity that correlates with cognitive and neurobehavioral changes. Also, our cholinergic biomarkers may identify whether individuals with DS are likely to respond to pro-cholinergic interventions, including the novel cholinergic modulators that are being developed to enhance cholinergic-sensitive cognitive functioning. The investigators anticipate using the data gathered here to inform future treatment studies in TRC-DS and beyond where novel cholinergic treatments may offer opportunities for early intervention in DS and be complementary to disease-modifying approaches such as anti-amyloid treatments.
Interventions:
description: Participants will be administered an [18F]-fluoroethoxybenzovesamicol (FEOBV) radiotracer for diagnostic imaging purposes (PET scan).
name: [18F]-FEOBV Radiotracer
other_name: [18F]-fluoroethoxybenzovesamicol
type: Drug
Study arms:
design_group_description: Adults between 18-55 with Down Syndrome.
design_group_title: Down Syndrome
design_group_type: Experimental
Sponsor: Vanderbilt University Medical Center
Collaborators: Vanderbilt Kennedy Center
Drug name mappings:
name: [18F]-FEOBV
lang: EN
Clinical trial NCT05572476: Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
Official title: Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer
Conditions: Small Cell Lung Cancer
Platinum-Sensitive Lung Small Cell Carcinoma
Extensive-stage Small-cell Lung Cancer
Summary: Multicenter, prospective, open-labeled, 2-arm, randomized non-comparative (2:1) phase II trial assessing the efficacy of lurbinectedin in association with durvalumab
Interventions:
description: A treatment cycles consists of 3 weeks (i.e. 21 days). Lurbinectedin will be administered by intravenous infusion on Day 1 every 3 weeks.<br/>Durvalumab will be administered by intravenous infusion on Day 1 every 3 weeks.
name: Association of lurbinectedin and durvalumab
type: Drug
description: Treatment will be administered on a 21-days cycle basis up to a maximum of 6 cycles.<br/>Carboplatin will be administered by intravenous infusion on Day 1 every 3 weeks.<br/>Etoposide will be administered by intravenous infusion on Day 1-3 every 3 weeks
name: Association of carboplatin and etoposide
type: Drug
Study arms:
design_group_description: Patients with with platinum sensitive extensive stage small-cell lung cancer (SCLC) which failed one prior platinum-containing regimen will be treated by the association of lurbinectedin and durvalumab
design_group_title: Experimental Arm A: treatment by lurbinectedin and durvalumab
design_group_type: Experimental
design_group_description: Patients with with platinum sensitive extensive stage small-cell lung cancer (SCLC) which failed one prior platinum-containing regimen will be treated by the association of carboplatin and etoposide
design_group_title: Standard Arm B: treatment by carboplatin and etoposide
design_group_type: Other
Sponsor: Institut Bergonié
Collaborators: Pharma Mar SA
AstraZeneca PLC
Drug name mappings:
name: 芦比替定
lang: CN
name: Lurbinectedin
lang: EN
name: 度伐利尤单抗
lang: CN
name: Durvalumab
lang: EN
name: デュルバルマブ（遺伝子組換え）
lang: JP
Clinical trial NCT00000229: Buprenorphine Detox With Two Types of Treatment. BBD II - 11
Official title: Buprenorphine Detox With Two Types of Treatment. BBD II
Conditions: Opioid-Related Disorders
Summary: The purpose of this study is to compare overall treatment outcome between behavioral versus enhanced behavioral treatment types.
Interventions:
name: Buprenorphine
type: Drug
Study arms:
Sponsor: University of Vermont
Collaborators: National Institute on Drug Abuse
Drug name mappings:
name: 丁丙诺啡
lang: CN
name: Buprenorphine
lang: EN
name: ブプレノルフィン
lang: JP
Clinical trial NCT06295094: The Efficacy of PIPAC and Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients.
Official title: The Efficacy of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) Combined With CURativE Intent Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. A Multicentre, Randomised, Open-label Phase-II Study
Conditions: Gastric Cancer
Chemotherapy, Adjuvant
Peritoneal Metastases
Minimally Invasive Surgical Procedures
Summary: The goal of this randomized clinical trial is to investigate whether pressurized intraperitoneal chemotherapy (PIPAC), delivered immediately after minimally invasive D2 gastrectomy and repeated 6-8 weeks later, improves 12-month peritoneal disease-free survival in patients with high-risk gastric adenocarcinoma when compared to standard treatment.
Interventions:
description: 10.5 mg/m2 body surface in 150ml saline
name: Cisplatin
type: Drug
description: 2.1 mg/m2 body surface in 50ml saline
name: Doxorubicin
type: Drug
Study arms:
design_group_description: In the intervention arm, conventional pressurized intraperitoneal chemotherapy (PIPAC) with cisplatin (10.5 mg/m2 body surface in 150ml saline) and doxorubicin (2.1 mg/m2 body surface in 50ml saline) is performed through Medical Device Regulation (MDR) class IIb the CE-certified nebuliser by certified PIPAC surgeons directly after the completion of the minimally invasive gastric resection and reconstruction using the remaining relevant ports. Chemotherapy is administered through a CE-certified nebulizer according to the manufacturer's manual and followed by 30 minutes of simple diffusion. The carbondioxide is evacuated through a closed system, and the abdominal wall is closed according to local surgical standards.<br/>The same procedure is repeated, incorporating the same compounds and dose regimens six to eight weeks postoperatively and before the start of the adjuvant part of the perioperative systemic chemotherapy.
design_group_title: Pressurized intraperitoneal chemotherapy (PIPAC)
design_group_type: Experimental
design_group_description: In the control arm, patients will undergo minimally invasive D2 gastrectomy
design_group_title: Standard
design_group_type: No Intervention
Sponsor: Odense University Hospital
Collaborators: Karolinska University Hospital
Drug name mappings:
name: 盐酸多柔比星
lang: CN
name: Doxorubicin Hydrochloride
lang: EN
name: ドキソルビシン塩酸塩
lang: JP
name: 顺铂
lang: CN
name: Cisplatin
lang: EN
name: シスプラチン
lang: JP
Clinical trial NCT06987643: A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
Official title: A Double-Blind, Placebo-Controlled, Proof-of-Concept Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod on Recovery After Moderate to Severe Acute Ischaemic Stroke
Conditions: Moderate to Severe Acute Ischaemic Stroke
Ischaemic Stroke
Summary: The purpose of this interventional study is to determine whether neflamapimod can improve residual physical disability and/or cognitive dysfunction after Moderate to Severe Acute Ischaemic Stroke.
Interventions:
description: Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase14 (p38α) provided in 40mg capsules
name: Neflamapimod
other_name: VX-745
type: Drug
description: Placebo is a capsule that looks just like neflamapimod but without the active ingredients
name: Placebo
type: Drug
Study arms:
design_group_description: Neflamapimod will be administered with food for 12 weeks in subjects with Moderate to Severe Acute Ischaemic Stroke. Subjects will receive 3 capsules per day (TID) with food (i.e., with the morning, mid-day and evening meals).
design_group_title: Cohort 1 neflamapimod
design_group_type: Active Comparator
design_group_description: Placebo will be administered with food for 12 weeks in subjects with Moderate to Severe Acute Ischaemic Stroke. Subjects will receive 3 capsules per day (TID) with food (i.e., with the morning, mid-day and evening meals).
design_group_title: Cohort 1 placebo
design_group_type: Placebo Comparator
design_group_description: Placebo will be administered with food for 12 weeks in subjects with Moderate to Severe Acute Ischaemic Stroke. Subjects will receive 2 capsules twice per day (BID) with food (i.e., with the morning and evening meals).
design_group_title: Cohort 2 placebo
design_group_type: Placebo Comparator
design_group_description: Neflamapimod will be administered with food for 12 weeks in subjects with Moderate to Severe Acute Ischaemic Stroke. Subjects will receive 2 capsules twice per day (BID) with food (i.e., with the morning and evening meals).
design_group_title: Cohort 2 neflamapimod
design_group_type: Active Comparator
Sponsor: EIP Pharma, Inc.
Collaborators: CervoMed, Inc.
Drug name mappings:
name: Neflamapimod
lang: EN
Clinical trial NCT07110844: Teclistamab-Daratumumab in AL Amyloidosis
Official title: A Phase 2 Clinical Trial of Teclistamab and Daratumumab in Previously Untreated AL Amyloidosis
Conditions: Amyloid Light-chain Amyloidosis
Summary: The purpose of this study is to investigate whether teclistamab-daratumumab combination is effective and safe in AL amyloidosis.
The study treatment is divided into cycles (C) and each cycle is 28 days (D). Study treatment is expected to last 6 months.
Interventions:
description: Teclistamab is a T-cell redirecting bispecific antibody (BsAb) targeting CD3 on T-cells and B-cell maturation antigen (BCMA) on plasma cells.
name: Teclistamab
other_name: TECVAYLI
teclistamab-cqyv
type: Drug
description: Daratumumab is an monoclonal antibody that targets the CD38 protein on the surface of myeloma cells.
name: Daratumumab and Hyaluronidase-fihj
other_name: DARZALEX FASPRO
Daratumumab
type: Drug
Study arms:
design_group_description: All participants in this study will receive teclistamab and daratumumab.
design_group_title: Teclistamab-Daratumumab
design_group_type: Experimental
Sponsor: Columbia University
Collaborators: Janssen Pharmaceuticals, Inc.
Drug name mappings:
name: 达雷妥尤单抗/重组人透明质酸酶PH20
lang: CN
name: Daratumumab/Hyaluronidase-fihj
lang: EN
name: ダラツムマブ（遺伝子組換え）/ボルヒアルロニダーゼ アルファ（遺伝子組換え）
lang: JP
name: 特立妥单抗
lang: CN
name: Teclistamab
lang: EN
name: テクリスタマブ（遺伝子組換え）（JAN）
lang: JP
Clinical trial NCT00434668: Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer
Official title: Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lung Cancer (NSCLC): Toledo Trial
Conditions: Non-small Cell Lung Cancer
Summary: The aim of this study is to evaluate the tolerability (in terms of drug delivery and toxicity) of four cycles of adjuvant docetaxel plus cisplatin in patients with completely resected stage IB-II Non-Small Cell Lung Cancer. To avoid a selection bias, eligible patients will be randomised to receive cisplatin/docetaxel or cisplatin/vinorelbine.
Interventions:
name: cisplatin/docetaxel
type: Drug
name: cisplatin/vinorelbine
type: Drug
Study arms:
Sponsor: Antwerp University Hospital
Collaborators: Sanofi
University of Antwerp
Drug name mappings:
name: 长春瑞滨双酒石酸盐
lang: CN
name: Vinorelbine Tartrate
lang: EN
name: ビノレルビン酒石酸塩
lang: JP
name: 多西他赛
lang: CN
name: Docetaxel
lang: EN
name: ドセタキセル
lang: JP
name: 顺铂
lang: CN
name: Cisplatin
lang: EN
name: シスプラチン
lang: JP
Clinical trial NCT01295307: Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Official title: Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia
Summary: In relapsed or refractory AML allogeneic HCT is considered to be the only treatment by which long-term disease-free survival can be achieved. Despite this favorable prospect, even in younger patients with relapsed AML only about 40% of the patients reach allogeneic HCT. A number of factors contribute to this low rate of transplantation, among them moderate activity of the salvage regimens and accumulating toxicities which prevent from transplantation; Prospective clinical trials in this indication usually focus either on the rate of CR achieved after a defined number of cycles of salvage therapy or on transplantation modalities. The consequent integration of salvage therapy into a transplant strategy accounting for the time-dependent process of donor search has not been studied so far.
The objective of this study is to evaluate the safety and efficacy of clofarabine salvage therapy prior to allogeneic HCT.
Interventions:
description: Induction and consolidation therapy / conditioning therapy with Clofarabine
name: Clofarabine
type: Drug
Study arms:
design_group_description: Induction therapy with clofarabine/cytarabine. Post-remission therapy with either allogeneic HCT after conditioning with clofarabine/melphalan if a donor is available, or clofarabine/cytarabine if no donor is available
design_group_title: Single Arm
design_group_type: Experimental
Sponsor: Dresden University of Technology
Collaborators: Genzyme Corp.
Drug name mappings:
name: 氯法拉滨
lang: CN
name: Clofarabine
lang: EN
name: クロファラビン
lang: JP
Clinical trial NCT06440954: Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
Official title: To Investigate the Efficacy and Resistance Mechanisms of Intrathecal Pemetrexed in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Harboring Oncogenic Mutations With Leptomeningeal Metastases
Conditions: Non-Small Cell Lung Cancer
Summary: This is a prospective interventional study clinical study to investigate the efficacy and resistance mechanisms of intrathecal pemetrexed in patients with driver gene mutations advanced NSCLC with leptomeningeal metastases.
Interventions:
description: Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
name: Intrathecal pemetrexed
other_name: pemetrexed
type: Drug
Study arms:
design_group_description: Intrathecal pemetrexed
design_group_title: Intrathecal pemetrexed
design_group_type: Experimental
Sponsor: Hunan Cancer Hospital
Collaborators: Hunan Cancer Hospital
Drug name mappings:
name: 培美曲塞二钠
lang: CN
name: Pemetrexed Disodium Hydrate
lang: EN
name: ペメトレキセドナトリウム水和物
lang: JP
Clinical trial NCT03911076: Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL
Official title: A Randomized Double-Blind, Placebo-controlled Phase II Trial With Safety Run-In of Intramuscular pNGVL4a-Sig/E7(Detox)/HSP70 and TA-CIN for the Treatment of Patients With HPV16+ Atypical Squamous Cells of Undetermined Significance (ASC-US) or Cannot Exclude High Grade SIL (ASC-H) Cytology or Low-grade Squamous Intraepithelial Lesion (LSIL)
Conditions: ASC-US
ASC-H
LSIL
Summary: * To evaluate the safety and tolerability of the dual IM pNGVL4a Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen
* To evaluate the efficacy of dual IM pNGVL4a-Sig/E7(detox)/HSP70 DNA and single IM TA-CIN immunization regimen on Human Papillomavirus (HPV) 16 clearance by Month 6
Interventions:
description: pNGVL4a-Sig/E7(detox)/HSP70 (pBI-1, naked DNA plasmid priming vaccine) TA-CIN (HPV16 L2E7E6 fusion protein booster vaccine)
name: PVX-2
type: Biological
description: PBS and PGC
name: Placebo
type: Other
Study arms:
design_group_description: Prime: 3 mg pNGVL4a-Sig/E7(detox)/HSP70 DNA Boost: 0.1 mg TA-CIN protein
design_group_title: PVX-2
design_group_type: Experimental
design_group_description: Prime: PBS (Phosphate Buffered Saline) Boost: PGC (Phosphate Glycine Cysteine Buffer)
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Papivax Biotech, Inc.
Collaborators: PAREXEL International Corp.
Drug name mappings:
name: pNGVL4a-Sig/E7(Detox)/HSP70 and TA-CIN(Papivax Biotech, Inc.)
lang: EN
Clinical trial NCT00217568: Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Official title: A Phase II Trial of Docetaxel and Carboplatin for First Relapsed Platinum-Sensitive Stage III and IV Advanced Ovarian Cancer or Peritoneal Carcinoma
Conditions: Ovarian Cancer
Peritoneal Cavity Cancer
Summary: RATIONALE: Drugs used in chemotherapy, such as docetaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving docetaxel together with carboplatin works in treating patients with relapsed stage III or stage IV ovarian epithelial or primary peritoneal cavity cancer.
Interventions:
name: pegfilgrastim
type: Biological
name: carboplatin
type: Drug
name: docetaxel
type: Drug
Study arms:
Sponsor: Fred Hutchinson Cancer Research Center
Collaborators: National Cancer Institute
Drug name mappings:
name: 卡铂
lang: CN
name: Carboplatin
lang: EN
name: カルボプラチン
lang: JP
name: 多西他赛
lang: CN
name: Docetaxel
lang: EN
name: ドセタキセル
lang: JP
Clinical trial NCT06523621: Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
Official title: Nivolumab As An Adjunctive Therapy In Relapsed Refractory Multiple Myeloma Patients With Sub-Optimal Response To Idecabtagene Vicleucel
Conditions: Multiple Myeloma
Summary: This study is designed to evaluate if treatment with adjuvant nivolumab improves depth of response in patients with relapsed refractory multiple myeloma (RRMM) who achieve a less-than-ideal response to idecaptagene vicleucel.
Interventions:
description: 2 cycles of nivolumab at a dose of 480 mg given over approximately 30-minutes intravenously on Day 1 of each treatment cycle
name: Nivolumab
other_name: Opdivo
type: Drug
Study arms:
design_group_description: Nivolumab
design_group_title: Single Arm
design_group_type: Experimental
Sponsor: Wake Forest School of Medicine
Collaborators: Bristol Myers Squibb Co.
Drug name mappings:
name: 纳武利尤单抗
lang: CN
name: Nivolumab
lang: EN
name: ニボルマブ（遺伝子組換え）
lang: JP